Antimicrobial resistance

Dantas, Alessandra da Silva

doi:10.1111/mmi.14912

Cited by 8 publications

(7 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The increased number of global infectious diseases outbreaks including the recent COVID-19 pandemic 1 , together with the increasing burden of antimicrobial resistance 2 , call for a more coordinated approach across different countries in this field. Currently, different institutions often use heterogeneous data structures and idiosyncratic local codes to report similar results.…”

Section: Introductionmentioning

confidence: 99%

Towards interoperability in infection control: a standard data model for microbiology

Rinaldi,

Drenkhahn,

Gebel

et al. 2023

Sci Data

View full text Add to dashboard Cite

The COVID-19 pandemic has made it clear: sharing and exchanging data among research institutions is crucial in order to efficiently respond to global health threats. This can be facilitated by defining health data models based on interoperability standards. In Germany, a national effort is in progress to create common data models using international healthcare IT standards. In this context, collaborative work on a data set module for microbiology is of particular importance as the WHO has declared antimicrobial resistance one of the top global public health threats that humanity is facing. In this article, we describe how we developed a common model for microbiology data in an interdisciplinary collaborative effort and how we make use of the standard HL7 FHIR and terminologies such as SNOMED CT or LOINC to ensure syntactic and semantic interoperability. The use of international healthcare standards qualifies our data model to be adopted beyond the environment where it was first developed and used at an international level.

show abstract

Section: Introductionmentioning

confidence: 99%

Towards interoperability in infection control: a standard data model for microbiology

Rinaldi,

Drenkhahn,

Gebel

et al. 2023

Sci Data

View full text Add to dashboard Cite

show abstract

“…37 Metal oxide-based nanoparticles demonstrate potent antibacterial effects, especially against bacterial biofilms on medical devices, dental materials, and wound dressings. 38,39 However, safety issues restrict their use for systemic infections. Lipid-based nanoparticles, such as liposomes, emerge as popular vehicles for systemic and topical antibacterial therapies.…”

Section: Utilizing Nanotechnology and Host-directed Therapies To Addr...mentioning

confidence: 99%

“…The structural diversity of heterocyclic compounds allows for the rational design and synthesis of molecules with tailored antimicrobial activity and pharmacokinetic profiles. 36,38 One class of heterocyclic compounds that has garnered significant interest in antimicrobial drug discovery is quinolones. Quinolones inhibit bacterial DNA gyrase and topoisomerase IV, essential enzymes involved in DNA replication and repair, thereby disrupting bacterial cell division and proliferation.…”

Section: Heterocyclic Compoundsmentioning

confidence: 99%

Revolutionizing Antimicrobial Solutions Nanotechnology, CRISPR-Cas9 and Innovative Approaches to Combat Drug Resistance in ESKAPE Pathogens

Sachithanandan,

Deepalakshmi,

Rajamohamed

et al. 2024

J. Pure Appl. Microbiol.

View full text Add to dashboard Cite

Antimicrobial drug resistance within ESKAPE pathogens is a formidable global challenge, necessitating innovative solutions. This review explores a multifaceted strategy incorporating nanotechnology, CRISPR/Cas9, and other cutting-edge approaches to effectively combat multidrug resistance in ESKAPE bacteria. Nanotechnology presents a promising avenue through targeted drug delivery systems like antibiotic nanoparticles and antibiotic–antibody conjugates (AACs). While these nanostructures aim to enhance therapeutic efficacy and mitigate resistance spread, challenges such as anti-PEG antibodies and optimal drug release must be considered. Inspired by successful anticancer nanomedicines, nanotechnology seeks to optimize drug penetration and retention within infected tissues. The revolutionary CRISPR/Cas9 gene-editing technology offers a precise and tailored approach by selectively targeting and modifying bacterial resistance genes. This holds the potential to reverse or eliminate drug resistance in ESKAPE pathogens, though challenges like off-target effects and efficient delivery mechanisms require attention for clinical translation. Additionally, alternative approaches such as fecal microbial transplantation, bacteriophage therapy, and probiotic bacterial replacement are actively explored in clinical trials. These strategies diversify the arsenal against antibiotic resistance by targeting unique vulnerabilities in ESKAPE pathogens. A comprehensive and multidisciplinary strategy is imperative to effectively address antimicrobial drug resistance in ESKAPE pathogens. Integration of nanotechnology, CRISPR/Cas9, and emerging approaches offers a synergistic solution, holding promise in overcoming the challenges posed by these resilient multidrug-resistant bacteria. This review provides insights into current research, challenges, and potential breakthroughs, emphasizing the urgency for collaborative efforts to safeguard global health.

show abstract

“…However, the repeated use of the drugs in various settings, including human, animal, and environmental, has led to the emergence of antimicrobial resistance (AMR) in different types of microorganisms. Consequently, AMR has become a significant concern for public and environmental health over the last two decades, posing a substantial threat [ 4 ]. The timely identification of drug resistance is of utmost importance to prevent the spread of drug-resistant tuberculosis and reduce mortality rates.…”

Section: Introductionmentioning

confidence: 99%

Rifampicin Resistance Pattern of Mycobacterium tuberculosis Infection in Tertiary Care Hospital Settings

Ranganathan,

Carmelin,

Muthusamy

2024

Cureus

View full text Add to dashboard Cite

IntroductionMycobacterium tuberculosis (MTB), the causative agent of tuberculosis (TB), continues to pose a significant global health threat, with increasing concerns about antimicrobial resistance (AMR). This study aims to elucidate the AMR patterns of MTB infections in tertiary care hospital settings. Materials and methodsA retrospective analysis was conducted on 138 clinical samples collected from patients attending the outpatient ward with clinically suspected MTB infections from November 2022 to April 2023 in a tertiary care hospital, Saveetha Medical College and Hospital. The study focused on the sample isolates collected from various clinical specimens, such as sputum, pus, synovial fluid, wound swabs, and other forms of samples from the patients. The samples were processed and analyzed with routine microbiological confirmation tests using standard laboratory methods such as staining and culture. Further, the samples were subjected to a GeneXpert MTB/RIF assay to assess the resistance to Rifampicin (RIF). The results were interpreted, analyzed using standard statistical methods, and presented. ResultsThe findings revealed marked resistance of the clinical isolate MTB to TIF, with positive and negative results through various peak levels shown by GeneXpert. Out of the 138 samples screened by GeneXpert for resistance, 14 samples were found to be positive (10.14%). Resistance to the first-line drug, namely RIF, was observed in the study, raising concerns about the effectiveness of standard tuberculosis treatment regimens followed in the country. ConclusionThis study implies the urgency of monitoring and addressing AMR in MTB infections in tertiary care hospital settings. The emergence of resistance to even the first-line drugs necessitates continuous surveillance, the implementation of appropriate diagnostic strategies, and the development of effective treatment protocols. A comprehensive understanding of the AMR landscape in tuberculosis is crucial for optimizing therapeutic interventions, preventing the spread of drug-resistant strains, and ultimately curbing the global burden of tuberculosis.

show abstract

Antimicrobial resistance

Cited by 8 publications

References 16 publications

Towards interoperability in infection control: a standard data model for microbiology

Towards interoperability in infection control: a standard data model for microbiology

Revolutionizing Antimicrobial Solutions Nanotechnology, CRISPR-Cas9 and Innovative Approaches to Combat Drug Resistance in ESKAPE Pathogens

Rifampicin Resistance Pattern of Mycobacterium tuberculosis Infection in Tertiary Care Hospital Settings

Contact Info

Product

Resources

About